Effects of magnesium sulfate on cardiac conduction and refractoriness in humans

Magnesium has been used empirically for several decades in the treatment of atrial and ventricular arrhythmias in patients with normal and decreased serum magnesium levels. However, a systematic evaluation of the effects of magnesium on cardiac conduction and refractoriness in humans has not been described. In this study, the electrocardiographic and electrophysiologic effects of magnesium were determined in 10 patients with normal baseline serum magnesium and other electrolyte levels. Six grams of magnesium sulfate was administered intravenously over 6 minutes followed by a continuous infusion of 1 additional gram over 1 hour. Serum magnesium levels rose significantly from a baseline of 2.0 +/- 0.2 to 5.4 +/- 0.4 mg/dl (p less than 0.001). No significant change occurred in heart rate at rest, or in duration of the QRS complex or QT or QTc intervals during sinus rhythm. There were significant increases in sinus node recovery time (1,000 +/- 211 to 1,106 +/- 223 ms, p less than 0.01) and corrected sinus node recovery time (279 +/- 87 to 336 +/- 104 ms, p less than 0.05). Significant increases occurred in atrioventricular (AV) node conduction time during sinus rhythm (82 +/- 22 to 97 +/- 17 ms, p less than 0.02), in the atrial paced cycle length at which AV node Wenckebach block occurred (350 +/- 46 to 419 +/- 65 ms, p less than 0.01) and in the AV node relative refractory period (397 +/- 27 to 422 +/- 18 ms, p less than 0.05), functional refractory period (395 +/- 41 to 415 +/- 33 ms, p less than 0.05) and effective refractory period (306 +/- 67 to 338 +/- 38 ms, p less than 0.05).

This article has been cited by other articles:

				K. M Ho, D. J Sheridan, and T. Paterson Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis Heart, November 1, 2007; 93(11): 1433 - 1440. [Abstract] [Full Text] [PDF]

				W. M. van den Bergh, A. Algra, and G. J.E. Rinkel Electrocardiographic Abnormalities and Serum Magnesium in Patients With Subarachnoid Hemorrhage Stroke, March 1, 2004; 35(3): 644 - 648. [Abstract] [Full Text] [PDF]

				N Cohen, D Almoznino-Sarafian, R Zaidenstein, I Alon, O Gorelik, M Shteinshnaider, S Chachashvily, Z Averbukh, A Golik, Z Chen-Levy, et al. Serum magnesium aberrations in furosemide (frusemide) treated patients with congestive heart failure: pathophysiological correlates and prognostic evaluation Heart, April 1, 2003; 89(4): 411 - 416. [Abstract] [Full Text] [PDF]

				P. Brugada Magnesium: an antiarrhythmic drug, but only against very specific arrhythmias Eur. Heart J., July 2, 2000; 21(14): 1116 - 1116. [PDF]

				M. Frick, B. Darpo, J. Ostergren, and M. Rosenqvist The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation Eur. Heart J., July 2, 2000; 21(14): 1177 - 1185. [Abstract] [PDF]

				M.P. Ingemansson, B. Smideberg, and S.B. Olsson Intravenous MgSO4alone and in combination with glucose, insulin and potassium (GIK) prolong the atrial cycle length in chronic atrial fibrillation Europace, January 1, 2000; 2(2): 106 - 114. [Abstract] [PDF]

				E. H. Christiansen, L. Frost, F. Andreasen, P. Mortensen, P. E. B. Thomsen, and A. K. Pedersen Dose-related cardiac electrophysiological effects of intravenous magnesium. A double-blind placebo-controlled dose-response study in patients with paroxysmal supraventricular tachycardia Europace, January 1, 2000; 2(4): 320 - 326. [Abstract] [PDF]

				C. Takanaka, K. O. Ogunyankin, J.S.M. Sarma, and B. N. Singh Antiarrhythmic and Arrhythmogenic Actions of Varying Levels of Extracellular Magnesium: Possible Cellular Basis for the Differences in the Efficacy of Magnesium and Lidocaine in Torsade de Pointes Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(2): 125 - 134. [Abstract] [PDF]

				C. W. Christensen, M. A. Rieder, E. L. Silverstein, and N. E. Gencheff Magnesium Sulfate Reduces Myocardial Infarct Size When Administered Before but Not After Coronary Reperfusion in a Canine Model Circulation, November 1, 1995; 92(9): 2617 - 2621. [Abstract] [Full Text]

				J. Caspi, E. Rudis, I. Bar, T. Safadi, and M. Saute Effects of Magnesium on Myocardial Function After Coronary Artery Bypass Grafting Ann. Thorac. Surg., April 1, 1995; 59(4): 942 - 947. [Abstract] [Full Text]

				M. Shechter, E. Kaplinsky, and B. Rabinowitz The Rationale of Magnesium Supplementation in Acute Myocardial Infarction: A Review of the Literature Arch Intern Med, November 1, 1992; 152(11): 2189 - 2196. [Abstract] [PDF]

				L. A. Gould, R. Betzu, T. Vacek, R. T. Muller, V. Pradeep, and A. Scafa Magnesium Treatment Of Torsade de Pointes A Case Report Angiology, July 1, 1990; 41(7): 577 - 581. [Abstract] [PDF]